Researchers report positive results from the first placebo-controlled trial of anifrolumab, a human monoclonal antibody targeting type I interferon receptor in patients with lupus. Treatment with anifrolumab was well-tolerated and sustained reduction in lupus disease activity.
A new UK study of over 3,000 adults found that childhood financial circumstances significantly impact wellbeing in middle age (41-65). Financial hardship in childhood is also a concern for mental health, particularly as child poverty levels increase.
A phase 2 clinical trial has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus. The study found that patients treated with deucravacitinib experienced significant improvements in disease activity, with response rates ranging from 34% to 58% compared to placebo.
A recent clinical trial shows that genicular nerve blocks provide short-term pain relief for patients with knee osteoarthritis. Patients who received the blocks reported significant improvement in pain scores, particularly at weeks 2 and 4.
The Society for Neuroscience awards recognize outstanding career and research achievements in neuroscience. Richard Huganir receives the Ralph W. Gerard Prize for his work on synaptic plasticity and learning and memory. Ian Maze wins the Jacob P. Waletzky Award for his groundbreaking research on neuroepigenetics and addiction.